The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

The FDA on Friday signed off on Eli Lilly ’s therapeutic antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Lilly will market the therapy under the ...

Pharmaceutical company Eli Lilly has announced a further €927 million investment at its facility at Raheen in Limerick, creating a further 150 jobs there.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The ...

Amphastar Pharmaceuticals has seen significant growth since its IPO, with its stock price increasing over 500%. Learn more ...

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

For example, Nuvalent, Viridian Therapeutics and Cabaletta Bio have each said they could see disruptions ... Large pharma companies also face risks. Eli Lilly has tapped WuXi Apptec to produce some of ...